Bone and Mineral Disorders After Kidney Transplantation: Therapeutic Strategies

Overview

Journal Transplant Rev (Orlando)

Specialty General Surgery

Date 2014 Jan 28

PMID 24462303

Citations 10

Authors

Miklos Z Molnar

Mohamed S Naser

Connie M Rhee

Kamyar Kalantar-Zadeh

Suphamai Bunnapradist

Affiliations

Soon will be listed here.

Abstract

Mineral and bone diseases (MBD) are common in patients with chronic kidney disease who undergo kidney transplantation. The incidence, types and severity of MBD vary according to the duration of chronic kidney disease, presence of comorbid conditions and intake of certain medications. Moreover, multiple types of pathology may be responsible for MBD. After successful reversal of uremia by kidney transplantation, many bone and mineral disorders improve, while immunosuppression, other medications, and new and existing comorbidities may result in new or worsening MBD. Chronic kidney disease is also common after kidney transplantation and may impact bone and mineral disease. In this article, we reviewed the prevalence, pathophysiology, and impact of MBD on post-transplant outcomes. We also discussed the diagnostic approach; immunosuppression management and potential treatment of MBD in kidney transplant recipients.

Citing Articles

[What is confirmed in the treatment of metabolic acidosis in chronic kidney disease?].

Ritter A, Kuhn C, Mohebbi N Inn Med (Heidelb). 2024; 65(12):1209-1215.

PMID: 39514096 PMC: 11632079. DOI: 10.1007/s00108-024-01806-z.

Prevalence of Musculoskeletal and Metabolic Disorders in Kidney Transplant Recipients: A Systematic Review and Meta-Analysis.

Herreros-Carretero A, Berlanga-Macias C, Martinez-Vizcaino V, Torres-Costoso A, Pascual-Morena C, Hernandez-Castillejo L Transpl Int. 2024; 37():12312.

PMID: 38720821 PMC: 11076774. DOI: 10.3389/ti.2024.12312.

High risk of osteoporosis and fracture following solid organ transplantation: a population-based study.

Chen H, Lai Y, Yang Y, Gau S, Huang C, Tsai T Front Endocrinol (Lausanne). 2023; 14:1167574.

PMID: 37288297 PMC: 10242127. DOI: 10.3389/fendo.2023.1167574.

Mineral and bone disorder after kidney transplantation (KTx).

Neves C, Marques I, Custodio M J Bras Nefrol. 2021; 43(4 Suppl 1):674-679.

PMID: 34910805 PMC: 8823922. DOI: 10.1590/2175-8239-JBN-2021-S113.

The Effects of Immunosuppressive Treatment during Pregnancy on the Levels of Potassium, Iron, Chromium, Zinc, Aluminum, Sodium and Molybdenum in Hard Tissues of Female Rats and Their Offspring.

Styburski D, Zwierello W, Skorka-Majewicz M, Goschorska M, Baranowska-Bosiacka I, Kabat-Koperska J Int J Mol Sci. 2020; 21(23).

PMID: 33261165 PMC: 7731177. DOI: 10.3390/ijms21239038.

References

Ambrus C, Molnar M, Czira M, Rosivall L, Kiss I, Remport A . Calcium, phosphate and parathyroid metabolism in kidney transplanted patients. Int Urol Nephrol. 2009; 41(4):1029-38. DOI: 10.1007/s11255-009-9631-0. View

Brandenburg V, Floege J . Transplantation: An end to bone disease after renal transplantation?. Nat Rev Nephrol. 2012; 9(1):5-6. DOI: 10.1038/nrneph.2012.245. View

Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C . Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int. 2003; 63(3):1130-6. DOI: 10.1046/j.1523-1755.2003.00816.x. View

Coco M, Pullman J, Cohen H, Lee S, Shapiro C, Solorzano C . Effect of risedronate on bone in renal transplant recipients. J Am Soc Nephrol. 2012; 23(8):1426-37. PMC: 3402282. DOI: 10.1681/ASN.2011060623. View

Sampaio M, Molnar M, Kovesdy C, Mehrotra R, Mucsi I, Sim J . Association of pretransplant serum phosphorus with posttransplant outcomes. Clin J Am Soc Nephrol. 2011; 6(11):2712-21. PMC: 3359573. DOI: 10.2215/CJN.06190611. View

Grotz W, Nagel C, Poeschel D, Cybulla M, Uhl M, Strey C . Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol. 2001; 12(7):1530-1537. DOI: 10.1681/ASN.V1271530. View

Palmer S, McGregor D, Strippoli G . Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev. 2007; (3):CD005015. DOI: 10.1002/14651858.CD005015.pub3. View

Mikuls T, Julian B, Bartolucci A, Saag K . Bone mineral density changes within six months of renal transplantation. Transplantation. 2003; 75(1):49-54. DOI: 10.1097/00007890-200301150-00009. View

Malluche H, Monier-Faugere M, Herberth J . Bone disease after renal transplantation. Nat Rev Nephrol. 2009; 6(1):32-40. PMC: 4503388. DOI: 10.1038/nrneph.2009.192. View

10.

Miller J, Molnar M, Kovesdy C, Zaritsky J, Streja E, Salusky I . Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis. Pharmacoepidemiol Drug Saf. 2012; 21(11):1232-9. PMC: 4304639. DOI: 10.1002/pds.3349. View

11.

Coco M, Glicklich D, Faugere M, Burris L, Bognar I, Durkin P . Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol. 2003; 14(10):2669-76. DOI: 10.1097/01.asn.0000087092.53894.80. View

12.

Sanchez Fructuoso A, Maestro M, Perez-Flores I, Valero R, Rafael S, Veganzones S . Serum level of fibroblast growth factor 23 in maintenance renal transplant patients. Nephrol Dial Transplant. 2012; 27(11):4227-35. DOI: 10.1093/ndt/gfs409. View

13.

Schwarz C, Mitterbauer C, Heinze G, Woloszczuk W, Haas M, Oberbauer R . Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation. Kidney Int. 2003; 65(1):304-9. DOI: 10.1111/j.1523-1755.2004.00369.x. View

14.

Marcen R, Caballero C, Pascual J, Teruel J, Tenorio M, Ocana J . Lumbar bone mineral density in renal transplant patients on neoral and tacrolimus: a four-year prospective study. Transplantation. 2006; 81(6):826-31. DOI: 10.1097/01.tp.0000203557.36884.e3. View

15.

Singha U, Jiang Y, Yu S, Luo M, Lu Y, Zhang J . Rapamycin inhibits osteoblast proliferation and differentiation in MC3T3-E1 cells and primary mouse bone marrow stromal cells. J Cell Biochem. 2007; 103(2):434-46. DOI: 10.1002/jcb.21411. View

16.

Walsh S, Altmann P, Pattison J, Wilkie M, Yaqoob M, Dudley C . Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. Am J Kidney Dis. 2009; 53(5):856-65. DOI: 10.1053/j.ajkd.2008.11.036. View

17.

Velasquez-Forero F, Mondragon A, Herrero B, PENA J . Adynamic bone lesion in renal transplant recipients with normal renal function. Nephrol Dial Transplant. 1996; 11 Suppl 3:58-64. DOI: 10.1093/ndt/11.supp3.58. View

18.

Lertdumrongluk P, Lau W, Park J, Rhee C, Kovesdy C, Kalantar-Zadeh K . Impact of age on survival predictability of bone turnover markers in hemodialysis patients. Nephrol Dial Transplant. 2013; 28(10):2535-45. PMC: 3784839. DOI: 10.1093/ndt/gft290. View

19.

Patel S, Kwan J, McCloskey E, McGee G, Thomas G, Johnson D . Prevalence and causes of low bone density and fractures in kidney transplant patients. J Bone Miner Res. 2001; 16(10):1863-70. DOI: 10.1359/jbmr.2001.16.10.1863. View

20.

Lukert B, Raisz L . Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990; 112(5):352-64. DOI: 10.7326/0003-4819-112-5-352. View